A medtech com­pa­ny's SPAC merg­er falls flat, miss­ing on nine-fig­ure val­u­a­tion

The biotech bear mar­ket is not leav­ing medtech com­pa­nies out of its reach, as In­tegri­ty Im­plants, aka Ac­celus, is now dis­cov­er­ing.

Ac­celus and SPAC part­ner CHP Merg­er Corp. will no longer be join­ing hands in a re­verse merg­er, the com­pa­nies an­nounced late Fri­day. The pair had an­nounced last No­vem­ber that it would at­tempt to take Ac­celus, which fo­cus­es on mak­ing min­i­mal­ly in­va­sive surgery (MIS) a stan­dard of care in spine treat­ment, pub­lic through the $482 mil­lion blank check ve­hi­cle.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER